In this update, we delve into the latest developments with Corbus Pharmaceuticals (CRBP), examining whether the recent hit of our $40 target will lead to a correction to $32-$33 or propel the stock directly towards the $50s. With the 1.618 extension potentially setting a target at $59, we analyze the possibilities and implications for traders and investors.
CRBP Correction to the .618 level followed by a sideways triangle breakout that was very easy to see is heading towards my $40 target, based on the retracement our extension should actually get into the GETTEX:50S or $60s but my first conservative swing trade target is $40 psych.
CRBP On its way to $33 then $40 - I've shown two of my anticipated trajectories depending on whether $29-$20.50 is broken or not, I think we break that by Friday and see $33 psych by Friday, but $39.80 to $40 psych may take a few weeks, this is an ideal swing trade!
CRBP on track for $32 then $40 - We have been stalled at $28 but when that breaks $32-$33 should come quickly, followed by $40 prior high zone once that breaks (within a month is my forecast)
In today's analysis on TradingView, we're diving into the latest developments in the market. Join us as we examine key trends, potential breakout points, and short-term targets. Stay informed and make data-driven decisions for your trades. (Date: 2/21/2024)
Week Ahead Glance on Corbus Pharmaceuticals (Ticker: CRBP) as of February 4th, 2024, by Candlestick Ninja! 🌟 Discover the latest insights into CRBP's recent explosive breakout to $40, forming a bullish head and shoulders pattern. We'll explore how it temporarily weakened under $27.50 and why a break of $27.50, eventually $29, could propel us to $35 swiftly.
I
🚀 Corbus Pharmaceuticals (Ticker: CRBP) made headlines on January 26th, 2024, as its shares skyrocketed an astonishing 207% following the groundbreaking Phase 1 Cancer Study results for patients with nectin-4 positive tumors. 🌟
In this video, we delve into the incredible journey of CRBP stock, breaking down the technical analysis that fueled its meteoric rise....
CRBP retraced after it's 3x rise on positive cancer tests/trials. Settling out at the .382 Fibonacci retracement in a healthy triangle formation, with a bullish piercing candle formation underway we are primed for a rip towards $40+
Corbus Pharmaceuticals Holdings, Inc(#CRBP) in good demand area
Orange Zone is a place to enter but Considering SL:6.02
Long Term Target:71 means 800%
MidTerm Target:20 Measn 150%
Hello Traders!
The probability of what I analyzing, is to be true unless the opposite is proven
According to my analysis, this is my opinion about weekly chart for CORBUS PHARMACEUTICALS HOLDINGS (CRBP)
Feel free dear trader to share with me your opinion, and also your analysis & Keep Watching
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve...
Stop loss can be so tight that it's probably not the worst gamble out there. Bullish divergence and trying to double bottom around earnings. It rallied on earnings in May so who knows. Very high risk, the company has weak fundamentals.
Fundamentals have been rough as of lately for CRBP. phase 3 reaching a critical pivot point for their most recent potential product. this aside, technically speaking we are gathering a cluster of moving averages with the captain 200 day MA getting ready to cross the 9,20,50. Im semi bullish because of its current consolidation its forming on the daily chart, going...
No investment advice!
I do this only for practicing.
Most info on the Chart
June 2-5 there are coming Data of their Lenabasum
We might see a continoung pre run up before the data will be released.
Cannabis related stock, as the cannabis sector is heating up.
Depending on the Data wie might see a big upside breakout, or back sub 1.
